Last reviewed · How we verify

NCT05544383

Effectiveness of an Interdisciplinary Pain Education Program in Public Health: a Pragmatic Clinical Trial

Status unknown NA Last updated 16 September 2022
What this trial tests

NA trial testing Interdisciplinary Pain Education Program in Musculoskeletal Pain in 108 participants. Status unknown.

Timeline
1 October 2022
Primary endpoint
1 June 2023
30 June 2023

Quick facts

Lead sponsorFederal University of Espirito Santo
PhaseNA
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingsingle
Primary purposetreatment
Enrollment108
Start date1 October 2022
Primary completion1 June 2023
Estimated completion30 June 2023

Drugs / interventions tested

Conditions studied

Sponsor

Federal University of Espirito Santo

Who can join

18 and older, any sex, with Musculoskeletal Pain. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The objective of this study is to evaluate the effectiveness of an interdisciplinary pain education program in improving self-efficacy and promoting quality of life in patients with chronic musculoskeletal pain in public health. This is a pragmatic clinical trial carried out with patients referred to the Physical Therapy sector of a municipality who will be allocated in an interdisciplinary pain education intervention group or a comparison group of conventional physical therapy treatment.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Musculoskeletal Pain

Currently open trials in the same condition.

Other Federal University of Espirito Santo trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05544383.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing